|
Characterization of Epigenetic Drug Discovery
Epigenetic modifications such as DNA methylation, histone
methylation, and deacetylation have been demonstrated
to regulate a wide range of physiological and pathological
processes. It is also well established that epigenetic
alterations can be used as the biomarkers and therapeutic
targets in many diseases, especially cancer. This has
led drug and biotechnology companies to actively search
for intervention agents of epigenetic alterations. To
better meet your needs at each stage of drug discovery
continuum, Epigentek now offers its service for the discovery
of drugs that aim at epigenetic targets. Our services
will enable you to:
- Enhance your drug discovery and development without
the burden of increased staff and equipment.
- Choose better drug candidates for further development.
- Determine specificity of the lead candidates against
a wide range of epigenetic targets.
- Validate the lead candidates in a rapid, reliable,
and high throughput assay format.
Our discovery service platforms
include:
Epigenase™ Epigenetic Enzyme Inhibitor Screening System
EpiModifer™ Epigenetic Modulator Screening System
These screening systems can enable the drug candidates
to be tested in situ and in vitro.
Contact us at services@epigentek.com
| 
| | 
